According to the announcement of Aosaikang Pharm ("ASK Pharm"), Jiangsu Aosaikang Pharmaceutical Co., Ltd. ("Jiangsu ASK Pharm"), a subsidiary of ASK Pharm, Lianyungang Guike Pharmaceutical Co., Ltd. ("Guike Pharmaceutical") and the shareholders of Guike Pharmaceutical--Kong Yin and Suzhou Lanxite Biotechnology Co., LTD. have jointly signed an investment agreement. Jiangsu ASK Pharm plans to inject money into Guike Pharmaceutical with its own capital of 36 million yuan. After the capital increase, Jiangsu ASK Pharm will obtain 33.96% equity of Guike Pharmaceutical.
Guike Pharmaceutical is a high-tech integrated pharmaceutical enterprise focusing on research, development, production, and sales of pharmaceutical raw materials. The capital increase will be used for the construction of the pharmaceutical raw materials workshop. ASK Pharm and its subsidiaries will fully participate in the process design, equipment selection and other work.
The workshop will be used to support the R&D and production of ASK Pharm and its subsidiaries, speed up the product transformation, and enhance competitiveness.
Founded in January 2003, Jiangsu ASK Pharm is a research-based pharmaceutical enterprise that integrates and streamlines innovative research and development with the manufacture, marketing promotion and sales of proprietary pharmaceuticals, fine chemicals, and health-care products.
At present, Jiangsu ASK Pharm has established a systematical administration and operation structure, with a comprehensive management system, superior R&D facility, state-of-the-art manufacturing capacity, sustainable product quality assurance, professional sales network, and after-marketing drug use monitoring and surveillance.
Jiangsu ASK Pharm specializes in proton pump inhibitor (PPI) products and oncology medicines. Its specialization and expertise in lyophilized parenteral products are unique and top-notch in China. Its GMP facilities have consecutively passed both national and provincial certifications for 11 times.